TTR and amyloidosis: It should also be stressed that the use of a lipid-based nanocarrier, already used in the treatment of hereditary transthyretin-mediated amyloidosis or for vaccination against COVID-19, is proposed here for the delivery of anti-miRNA into the CNS, representing a strategy capable of generating technological improvements not only in the ischemic cerebral pathology under study, but also in numerous other unexplored neurodegenerative diseases.